Lexpos News

Pharmacy teams should be aware that the brand Nystan® 100,000units/ml oral suspension (ready mixed) (Vygoris Ltd) 30 ml has been discontinued and is no longer available for community pharmacies to order. Zydus Pharmaceuticals UK Ltd has introduced a generic version of Nystatin 100,000units/ml oral suspension, which is available to order from wholesalers. Please note, where [...]

The post Discontinuation of Nystan® 100,000units/ml oral suspension (ready mixed) (Vygoris Ltd) appeared first on Community Pharmacy England.

Department of Health and Social Care (DHSC) has issued a medicine supply notification for Tolterodine 2mg and 4mg modified-release capsules MSN/2025/032 Tier 2 – medium impact Date of issue: 20th May 2025 Phenobarbital 15mg/5ml elixir (500ml) is out of stock until late June 2025. Specials of phenobarbital 15mg/5ml oral solution and phenobarbital 15mg/5ml oral suspension [...]

The post Medicine Supply Notification: Phenobarbital 15mg/5ml elixir appeared first on Community Pharmacy England.

Department of Health and Social Care (DHSC) has issued a medicine supply notification for Tolterodine 2mg and 4mg modified-release capsules MSN/2025/031 Tier 2 – medium impact Date of issue: 20th May 2025 Tolterodine 2mg and 4mg modified-release (MR) capsules are in limited supply until mid-August and mid-September 2025, respectively. Tolterodine 1mg and 2mg immediate release [...]

The post Medicine Supply Notification: Tolterodine 2mg and 4mg modified-release capsules appeared first on Community Pharmacy England.

Community Pharmacy England has joined forces with the Taskforce for Lung Health to call for pharmacies to be given a bigger role in supporting lung health to improve respiratory health outcomes, enhance access to care, and ease winter pressures on the NHS. A new joint Action Plan to help prevent a future winter respiratory health [...]

The post Call to expand pharmacy respiratory services to help tackle winter health pressures appeared first on Community Pharmacy England.

Following an update to the National Institute for Health and Care Excellence (NICE) guidance on antiviral treatment for COVID-19,  which removes some of the cohorts of patients eligible for these treatments, these changes will also need to be reflected in the Lateral Flow Device (LFD) service. The changes in the NICE guidance means the following [...]

The post LFD service: Changes to patient cohort eligibility appeared first on Community Pharmacy England.